Quoin Pharmaceuticals, Inc. (QNRX), a clinical-stage specialty pharmaceutical company, on Tuesday, announced positive interim clinical data from its ongoing pediatric study evaluating QRX003, an investigational treatment for Netherton Syndrome, a rare and severe skin disorder.
In the pediatric trial, the first subject treated twice daily with QRX003 for six weeks showed significant improvement.
The Investigator's Global Assessment (IGA) of the skin condition improved from "Severe" to "Mild" after just six weeks of dosing. Due to these encouraging results, the treatment area was expanded to cover the whole body.
No safety concerns or adverse events have been reported to date, in line with observations from other ongoing studies. These results highlight QRX003's potential as an effective treatment for Netherton Syndrome, which currently has no approved therapies.
Dr. Michael Myers, CEO of Quoin Pharmaceuticals, commented, "The significant improvement observed in this pediatric patient is a positive development in our efforts to bring a much-needed treatment to Netherton Syndrome patients. We are excited to continue expanding this study and remain committed to advancing QRX003 as a potential treatment."
Four clinical studies evaluating QRX003 as a treatment for Netherton Syndrome are underway.
Cash position:
Quoin had approximately $10.3 million in cash, cash equivalents, and marketable securities as of Sept. 30, 2024. This is expected to fund the Company's operations into late 2025.
QNRX closed Monday's (Jan. 13, 2025) trading at $0.57 down 8.02%. In premarket trading, the stock is up 9.35% at $0.62.
For comments and feedback: editorial@rttnews.com